Although 33 pathways were present in a certain SGLT2 inhibitor, a total of 125 pathways were overlapped in two or more SGLT2 inhibitors, and these overlapping pathways included the four key pathways analyzed in the previous KEGG analysis results, that is, Rap1 signaling pathway, MAPK signaling pathway, EGFR tyrosine kinase inhibitor resistance and AGE-RAGE signaling pathway in diabetic complications, which demonstrates that the four pathways play an important role in the treatment of SGLT2 inhibitors in DM with HF. This evidence concerns the gene RENBP and diabetes mellitus.